TY - JOUR
T1 - Neurological Complications in COVID-19 Patients
T2 - Can Analysis of Specific Antibodies and Viral RNA in Paired Cerebrospinal Fluid and Serum be Used for Accurate Diagnosis of SARS-CoV-2 Neuroinflammatory Disease? A Case Series
AU - Lauridsen, Karin Holst
AU - Olsen, Kristine Boisen
AU - Lund, Eva Løbner
AU - Jensen, Tomas O
AU - Pedersen, Thomas Ingemann
AU - Harboe, Zitta Barrella
AU - Antsupova, Valeria
AU - Rasmussen, Lasse Dam
AU - Röser, Dennis
AU - Banner, Jytte
AU - Franck, Kristina Træholt
AU - Vorobieva Solholm Jensen, Veronika
N1 - © The Author(s) 2022.
PY - 2022/12
Y1 - 2022/12
N2 - BACKGROUND: Neurological complications during and after SARS-CoV-2 infection have been frequently described. The detection of either SARS-CoV-2 RNA or specific antibodies against SARS-CoV-2 in cerebrospinal fluid in the context of concomitant neurological manifestations indicates neuroinfection.METHODS AND RESULTS: This is a retrospective descriptive analysis of cerebrospinal fluids and serum samples from 2 hospitalized patients and autopsy findings from 2 patients who died at home. Samples were analysed by 3 independent enzyme-linked immunosorbent assays. Specific antibodies against SARS-CoV-2 were detected in cerebrospinal fluids and paired serum in all 4 cases. Levels of antibodies in cerebrospinal fluids were highest in samples from a deceased man with critical progression of COVID-19 and detectable SARS-CoV-2 viral RNA in cerebrospinal fluid, serum, 4 brain biopsies and 15 additional tissue samples, though immunohistochemical staining for SARS-CoV-2 in brain tissue did not detect the virus.CONCLUSION: Detection of SARS-CoV-2 antibodies in paired serum and cerebrospinal fluid may support the presence of SARS-CoV-2 neuroinflammatory disease in patients with COVID-19 and neurological manifestations.
AB - BACKGROUND: Neurological complications during and after SARS-CoV-2 infection have been frequently described. The detection of either SARS-CoV-2 RNA or specific antibodies against SARS-CoV-2 in cerebrospinal fluid in the context of concomitant neurological manifestations indicates neuroinfection.METHODS AND RESULTS: This is a retrospective descriptive analysis of cerebrospinal fluids and serum samples from 2 hospitalized patients and autopsy findings from 2 patients who died at home. Samples were analysed by 3 independent enzyme-linked immunosorbent assays. Specific antibodies against SARS-CoV-2 were detected in cerebrospinal fluids and paired serum in all 4 cases. Levels of antibodies in cerebrospinal fluids were highest in samples from a deceased man with critical progression of COVID-19 and detectable SARS-CoV-2 viral RNA in cerebrospinal fluid, serum, 4 brain biopsies and 15 additional tissue samples, though immunohistochemical staining for SARS-CoV-2 in brain tissue did not detect the virus.CONCLUSION: Detection of SARS-CoV-2 antibodies in paired serum and cerebrospinal fluid may support the presence of SARS-CoV-2 neuroinflammatory disease in patients with COVID-19 and neurological manifestations.
UR - http://www.scopus.com/inward/record.url?scp=85142762469&partnerID=8YFLogxK
U2 - 10.1177/2632010X221139096
DO - 10.1177/2632010X221139096
M3 - Journal article
C2 - 36448025
VL - 15
SP - 2632010X221139096
JO - Clinical pathology (Thousand Oaks, Ventura County, Calif.)
JF - Clinical pathology (Thousand Oaks, Ventura County, Calif.)
SN - 2632-010X
ER -